Skin Tissue Replacement-Executive summary

Skin Tissue Replacement-Executive summary - Executive...

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
Executive Summary Skin Tissue Replacement RepliDerm Inc. will produce a synthetic dermal replacement to treat burns, diabetic ulcers, and other serious wounds. The goal of the dermal replacement is to create a matrix scaffold for new blood vessels to form. After the matrix is completely vascularized, a very thin epidermal graft will be applied over the matrix. Once this is done, the wound will heal and have all of the same properties as normal skin, except for sweat glands and hair follicles. This dermal replacement is a 6 inch by 4 inch sheet constructed of bovine collagen implanted with vascular endothelial growth factor (VEGF) microspheres. The VEGF microspheres decrease the amount of time needed for the body to vascularize the matrix compared to just collagen alone. Quicker vascularization means a shorter stay in the hospital and a smaller hospital bill for the patient. It is estimated that it will take RepliDerm Inc. approximately 15 years and cost $351,000,000 to pass the FDA trials that are required for bringing a product such as this
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 08/31/2011 for the course CHE 4273 taught by Professor Staff during the Spring '10 term at Oklahoma State.

Ask a homework question - tutors are online